Welcome to the e-CCO Library!

P379: Variations in disease monitoring between Inflammatory Bowel Disease patients on intravenous and subcutaneous biologic agents.
Year: 2021
Source: ECCO'21 Virtual
Authors: Hilley, P.(1);Li Wai Suen, C.(1,2);Srinivasan, A.(1,2);Choy, M.C.(1,2);De Cruz, P.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P380 What is the optimal dose of thiopurinic drugs (azatioprine) in patients with inflammatory bowel disease under treatment combined with anti-TNFα (infliximab/adalimumab)?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. LUCAS RAMOS, C. Suarez Ferrer, M. Sanchez Azofra, J. Poza Cordón, E. Martín Arranz, M.D. Martin Arranz

Created: Thursday, 30 January 2020, 10:12 AM
P380: A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Danese*1, A. Hart2, A. Dignass3, G. Fiorino1, E. Louis4, G. D'Haens5, I. Dotan6,7, G. Rogler8, K. Paridaens9, L. Peyrin-Biroulet10

Created: Friday, 22 February 2019, 9:41 AM
P380: Assessment of the awareness and education of vaccination in our IBD cohort: an observational study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Maheshwari P., Palaniappan S.K., Moran C., Forry M., Parihar V., Hall B., Reilly M., O'Toole A.

Created: Wednesday, 20 February 2019, 10:36 AM
P380: Changes in faecal microbiome and metabolome are more pronounced in Crohn's disease patients who adhered to the CD-TREAT diet and responded by calprotectin.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Svolos, V.(1)*;Hansen, R.(2);Russell, R.K.(3);Gaya, D.R.(4);John Paul, S.(5);Macdonald, J.(5);Wilson, D.(3);Henderson, P.(3);Din, S.(6);Ho, G.T.(6);Quince, C.(7);Ijaz, U.Z.(8);Milling, S.(9);Nichols, B.(1);Papadopoulou, R.(1);McKirdy, S.(1);Gervais, L.(2);Shields, S.(5);Gerasimidis, K.(1);
Created: Friday, 14 July 2023, 11:05 AM
P380: Comparative study of infliximab and adalimumab induction therapy for clinical remission and mucosal healing in paediatric patients with active Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Szymanska*1, M. Dadalski2, S. Szymanska3, W. Grajkowska3, M. Pronicki3, K. Jaroslaw2

Created: Friday, 22 February 2019, 9:49 AM
P380: Comparison of mucosal healing through segments of ileocolonic Crohn’s disease treated with biologics
Year: 2021
Source: ECCO'21 Virtual
Authors: Temido, M.J.(1);Portela, F.(1);Lopes, S.(1);Mendes, S.(1);Ferreira, M.(1);Ferreira, M.(1);Figueiredo, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P380: Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease
Year: 2022
Source: ECCO'22
Authors: Feagan, B.G.(1);Colombel, J.F.(2);Panaccione, R.(3);Schreiber, S.(4);Ferrante, M.(5);Kamikozuru, K.(6);Lee, W.J.(7);Griffith, J.(7);Kligys, K.(7);Kalabic, J.(8);Chen, N.(7);Dubinsky, M.(2);
Created: Friday, 11 February 2022, 3:52 PM
P380: Risk factors for poor postoperative outcome in patients with Crohn’s disease undergoing ileocaecal resection
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Labidi1*, M. Ben Abbes1, S. Hamdi1, H. Maghrebi2, N. Ben Mustapha1, M. Fekih1, L. Zouiten1, M. Serghini1, Z. Ben Safta2, J. Boubaker1

Created: Thursday, 21 February 2019, 9:14 AM
P381 Use of ustekinumab in Crohn’s disease: Singapore largest single-centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

H.H. Shim1, S.C. Kong1, W.C. Ong2, T.G. Lim2, P.W. Chan1

Created: Thursday, 30 January 2020, 10:12 AM
P381: Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Panaccione R.*1, Rutgeerts P.2, Sandborn W.3, Schreiber S.4, Colombel J.-F.5, Berg S.6, Maa J.-F.7, Petersson J.7, Robinson A.M.7

Created: Wednesday, 20 February 2019, 10:36 AM
P381: An observational study of adverse events of patients with inflammatory bowel disease receiving parenteral iron
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Wilson*, E. Murray, G. B. Turner

Created: Friday, 22 February 2019, 9:49 AM
P381: Factors predicting risk of colectomy in patients receiving first line steroid and second line biologic salvage therapy for Acute Severe Ulcerative Colitis
Year: 2022
Source: ECCO'22
Authors: Skinezes, Y.(1,2);Meir, Z.Y.(1,2);Abitbol, C.M.(1,2);Levartovsky, A.(1,2);Klang, E.(1,2);Kopylov, U.(1,2);Ben-Horin, S.(1,2);Ungar, B.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P381: Fatigue is an independent disease manifestation largely independent of chronicity, comorbidity and disease activity in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Risager Christensen, K.(1);Steenholdt, C.(1);Buhl, S.(1);Skougaard, M.(2);Brynskov, J.(1);Ainsworth, M.A.(3);Schjødt Jørgensen, T.(2);Kristensen, L.E.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P381: Infliximab induction regimes in steroid refractory acute severe colitis: a multi-centre retrospective cohort study with propensity score analysis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Sebastian*1,2, S. Myers1, N. Syed1, K. Argyriou3, G. Martin4, L. Los5, J. Fiske6, R. Ranjan7, B. Cooper8, N. Patel9, V. Goodoory10, F. Shaikh10, H. L. Ching11, N. Jayasooriya12, J. Brooks13, A. Dhar7, A. H. Shenoy8, J. Limdy6, J. Butterworth5, P. B. Allen4, S. Samuel3, G. Moran3, R. Shenderey10, G. Parkes12, A. Lobo11, S. Subramanian9, T. Raine14

Created: Friday, 22 February 2019, 9:41 AM
P381: Predictors of vedolizumab response to induction: Real-life experience
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Gutiérrez1,2*, L. Sempere1, M. Belvis3, J.M. Vázquez4, R. Laveda5, M. García6, F. Argüelles-Arias3, H. Pallarés4, L. Castro3, E. Gómez4, B. Maldonado3

Created: Thursday, 21 February 2019, 9:14 AM
P381: Ustekinumab trough levels are associated with sonographic transmural healing in Pediatric Inflammatory Bowel Disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kellar, A.(1)*;Aronskyy, I.(1);Dubinsky, M.C.(1);Dolinger, M.T.(1);
Created: Friday, 14 July 2023, 11:05 AM
P382 Application of enhanced recovery after surgery in single-port laparoscopic partial small intestine resection in the treatment of Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. LI, Z. Zhou, D. Yao, L. Zheng, Y. Duan, B. Liu, Y. Huang

Created: Thursday, 30 January 2020, 10:12 AM
P382: A panel of serum markers for early detection of endoscopic healing with infliximab in patients with ulcerative colitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

de Bruyn M.*1,2, Ringold R.3, Ferrante M.2,4, Van Assche G.2,4, Opdenakker G.1, Dukler A.3, Vermeire S.2,4

Created: Wednesday, 20 February 2019, 10:36 AM
P382: Combination therapy with TNF-inhibitors and immunomodulators are associated with shorter duration to first serious infection: the DEVELOP experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Escher*1, B. Gold2, J. Izanec3, C. Busse4, Y. Wang5, S. Cucchiara6

Created: Friday, 22 February 2019, 9:41 AM